Here's Why GSK (GSK) is a Strong Value Stock

Zacks Investment Research highlights GSK (GSK) as a compelling value stock, assigning it a Zacks Rank #2 (Buy) and a VGM Score of B. The company's Value Style Score of A is supported by a forward P/E ratio of 9.52, and the consensus earnings estimate for fiscal 2025 has increased by $0.12 to $4.32 per share following upward revisions from five analysts; GSK also has an earnings surprise of 8.6%.

Analysis

GSK plc (GSK) is presented as a noteworthy investment opportunity, primarily driven by its favorable metrics within the Zacks Investment Research framework. The company holds a Zacks Rank #2 (Buy) and a VGM Score of B, indicating a positive overall outlook. A key highlight is GSK's Value Style Score of A, supported by a compelling forward P/E ratio of 9.52, which suggests the stock may be undervalued relative to its earnings potential. Reinforcing this positive sentiment, five analysts have revised their earnings estimates upward for GSK's fiscal 2025 within the last 60 days. This collective revision has resulted in an increase of $0.12 in the Zacks Consensus Estimate, bringing it to $4.32 per share for fiscal 2025. Furthermore, GSK has demonstrated a consistent ability to exceed earnings expectations, evidenced by an average earnings surprise of 8.6%. These indicators, combined with a strongly positive sentiment score of 0.8 for the stock, point towards a robust fundamental picture for the company, which operates across Specialty Medicines, Vaccines, and General Medicines.

Key Decisions for Investors

• Investors, particularly those with a value-oriented strategy, should consider GSK given its #2 (Buy) Zacks Rank, A-rated Value Style Score, and attractive forward P/E ratio of 9.52.
• The recent upward revisions in fiscal 2025 earnings estimates by multiple analysts, resulting in a consensus of $4.32 per share, warrant attention as they signal strengthening confidence in GSK's profitability.
• GSK's consistent track record of delivering an average earnings surprise of 8.6% suggests operational efficiency and may indicate potential for continued outperformance, making it a candidate for further due diligence.